Cure Duchenne Hosts Drisapersen Update Webinar With GSK on May 6, 2013 Business Wire NEWPORT BEACH, Calif. -- April 30, 2013 CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will host a webinar on drisapersen with GlaxoSmithKline (GSK) on May 6, 2013 at 12 p.m. EDT for Duchenne parents and advocates. The purpose of the webinar is to update the Duchenne community about Phase II clinical trial results for GSK’s drisapersen drug for the treatment of Duchenne muscular dystrophy, a progressive muscle wasting disease that impacts 1 in 3,500 boys. GSK investigator John Kraus will present and answer submitted questions. CureDuchenne is hosting the webinar in collaboration with Parent Project Muscular Dystrophy and the Muscular Dystrophy Association to enable the Duchenne community and GSK to come together to further understand the drisapersen update for potential Duchenne treatments. Boys with Duchenne are usually diagnosed before the age of 5, in a wheelchair by age 12 and most don’t survive their mid-20s. There is currently no cure for Duchenne. To register for the “Drisapersen Update” webinar with the GSK on May 6 click here. Follow us on Facebook, Twitter and YouTube. About CureDuchenne CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials. Contact: CureDuchenne Karen Harley, 949-872-2552
Cure Duchenne Hosts Drisapersen Update Webinar With GSK on May 6, 2013
Press spacebar to pause and continue. Press esc to stop.